November 22, 2019
The potentially noxious effects of fluoride are a highly contested subject within the medical community and the public arena as previous research has hinted at the possibility of detrimental health consequences caused by drinking fluoridated water ranging from dental fluorosis to neurotoxicity. As fluoride crosses the placenta – accumulating in the brain regions associated with learning and memory – it may alter proteins and neurotransmitters in the central nervous system of the fetus, making it potentially neurotoxic.
Although still a controversial subject, increased fluoride exposure from community water fluoridation has been tied to lowered children’s IQ levels in past studies, prompting growing research efforts aimed at uncovering the link between prenatal fluoride exposure and IQ levels in offspring. A recently published prospective study implicates that high fluoride intake during pregnancy may be associated with a reduction in children’s IQ at ages 3 to 5 years, and potentially beyond.
November 20, 2019
Two decades ago, the oncology community was alerted to age disparities in cooperative group studies by an analysis of National Cancer Institute (NCI) funded trials. Older cancer patients have long been underrepresented in clinical trials, despite the disease primarily affecting the aging population. Researchers had not only investigated the disparities in age, but they also noted lesser representation of racial and ethnic minorities, and women.
The latest analysis of oncologic treatment clinical trial cohort demographics reveals a concerning lack of improvement in diversified representation, especially of the aging population. Today, the median age of trial participants is nearly 7 years younger than the median age of cancer patients and the age gap is worsening, according to new research published online in JAMA Oncology.
November 18, 2019
One of the top causes of disability across the globe, schizophrenia can significantly diminish educational, occupational and psychosocial performance, impairing the lives of millions of people worldwide. Although the severe chronic neurological disorder affects a small proportion of the population – around 1% – it is one of the most disabling conditions, especially if left untreated. Schizophrenia carries a substantial disease burden; people with the disorder face increased risks of premature mortality, suicide, and physical illness.
While research has yet to identify a definitive cause of schizophrenia, many factors are thought to contribute to the development of schizophrenia, including genetics, environment, and neurological changes. Previous research implicates that estrogen may play a significant role in the condition’s progression, with a prior randomized controlled trial revealing symptom improvement in premenopausal female patients treated with transdermal estradiol. These initial positive findings have not been replicated by other studies, including ones without commercial involvement.